Scienture Holdings (SCNX) Q3 2024 earnings summary

Executive summary

• Completed the Scienture Merger in July 2024, shifting focus to pharmaceutical R&D and divested non-core assets, including Softell and Superlatus.

• Changed corporate name to Scienture Holdings, Inc. and updated ticker to SCNX in September 2024.

• Declared and paid special cash dividends totaling $14.9 million in 2024.

Financial highlights

• Revenue for Q3 2024 was $64,861, down 83% year-over-year due to asset dispositions.

• Net loss from continuing operations for Q3 2024 was $3.18 million, compared to $88,136 in Q3 2023.

• For the nine months ended September 30, 2024, revenue was $83,560 (down 93% year-over-year), and net income was $16.2 million, driven by gains from discontinued operations.

• Gross margin for Q3 2024 was 5.99%, down from 10.09% in Q3 2023.

• Cash balance at September 30, 2024 was $579,103, up from $314 at year-end 2023, mainly from asset sales.

Outlook and guidance

• Management expects continued focus on integrating Scienture’s R&D, marketing IPS, and exploring strategic transactions for B2C subsidiaries.

• Estimated operating expenses and working capital needs for the next 12 months are $9.8 million.

• Additional capital will be required to support ongoing operations and growth; inability to raise funds may impact liquidity and growth.